Molecular Partners AG (NASDAQ:MOLN – Get Free Report)’s stock price traded down 0.2% during trading on Wednesday . The stock traded as low as $4.89 and last traded at $5.03. 1,564 shares were traded during trading, a decline of 71% from the average session volume of 5,427 shares. The stock had previously closed at $5.04.
Molecular Partners Stock Performance
The company has a market cap of $206.04 million, a price-to-earnings ratio of -2.37 and a beta of 1.06. The stock’s fifty day moving average is $5.31 and its two-hundred day moving average is $5.60.
About Molecular Partners
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.
See Also
- Five stocks we like better than Molecular Partners
- Conference Calls and Individual Investors
- IBM’s AI Bet Pays Off—What’s Next for Investors?
- How to trade using analyst ratings
- 3 Reasons to Treat AMD’s Drop as an Entry Opportunity
- What is Put Option Volume?
- Qualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
